Itching drug trial for dialysis patients halted early
NCT ID NCT04393675
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a skin-applied drug called LT5001 for severe itching in people on hemodialysis. The trial was stopped early after enrolling only 18 participants. The main goal was to check safety and how the drug behaves in the body, not to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LT5001 (a drug applied to the skin)
- What this could lead to
- If it had worked, this could have pointed toward a new treatment for severe itching in dialysis patients.
- What could go wrong
- The trial was terminated early with only 18 participants, so results are very limited. It is unclear if LT5001 is safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UREMIC PRURITUS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Medical University Hospital
Taichung, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.